AltPep develops diagnostic and therapeutic programs based on a library of custom designed synthetic peptides. The company targets early molecular triggers of amyloid diseases.

AltPep

AltPep develops early disease-modifying treatments and detection tools for amyloid diseases by targeting one of the earliest molecular triggers – toxic soluble oligomers.  These oligomers are associated with many diseases, including neurodegenerative diseases and type 2 diabetes. Decades of scientific research by the Daggett Research Group culminated in the discovery of a novel protein structure, alpha-sheet, the foundation of our innovative approach.

Our lead program aims to identify Alzheimer’s Disease long before symptoms occur and then neutralize the toxic soluble oligomers associated with the disease.

Matrix Capital Management

Alexandria Venture Investments

Partners Investment

Section 32 Senator Investment Group

Eli Lilly

We are excited to welcome Denis Sirringhaus to the AltPep team as Vice President of Business Development. Denis most recently served as Executive Director of Business Development at Caribou Biosciences, where he helped secure a $25M Pfizer investment that led to a $134.6M follow-on offering. Prior to Caribou, Denis worked in Business Development at several biopharma companies, including Gossamer Bio and Genentech/Roche where he evaluated neuroscience assets including the in-license of Enspryng and the acquisition of Spark Therapeutics. He started his career at JPMorgan on the Specialty Pharma equity research team. Denis has an MBA from Wharton, a Master’s of Biotech from University of Pennsylvania and an AB in Biological Sciences from Harvard. 

Denis’ experience is ideally suited to help foster the partnerships needed for AltPep to realize its goal of transforming the treatment and detection of amyloid diseases, such as Alzheimer’s.

Please join us in giving a warm welcome to Denis!

We're #hiring a new Research Associate - Peptide Production in Greater Seattle Area. Apply today or share this post with your network.

We're #hiring a new Associate Scientist - In Vivo Pharmacology/Biology in Seattle, Washington. Apply today or share this post with your network.

We're #hiring a new Scientist, In Vivo Pharmacology/Biology in Seattle, Washington. Apply today or share this post with your network.

We're #hiring a new Medical Laboratory Scientist in Seattle, Washington. Apply today or share this post with your network.

We're #hiring a new Scientist - Protein Biophysicist in Seattle, Washington. Apply today or share this post with your network.

UW published an interesting overview of the work led by Valerie Daggett identifying a link between bacterial infections and Alzheimer’s disease. 

Check out the article here https://lnkd.in/gK2P6XmZ

#Innovation #AlzheimerDisease #UW #Research

We are excited about the GeekWire Awards tomorrow! AltPep's Valerie Daggett has been nominated for Startup CEO of the year, along with some other great start-up CEOs. 

Last year AltPep won GeekWire’s Health Innovation of the Year award.

Hope to see you at the event! Get your GeekWire Awards tickets: https://lnkd.in/e5awbXau

#geekwireawards #innovation #AlzheimersDisease

AltPep CEO, Valerie Daggett presented at the 12th Annual Alzheimer’s and Parkinson’s Drug Development Summit today.

Her talk, titled “Diagnostics and Therapeutics for Selective Targeting of Early Toxic Oligomers” overviewed AltPep’s SOBA assay and SOBIN therapeutic in Alzheimer’s disease, as well as the application of AltPep’s platform to other amyloid diseases including Parkinson’s disease. 

Click below to read her bio and learn more about the Summit.

#innovation #AlzheimersDisease #ParkinsonsDisease #Research

AltPep CEO Valerie Daggett will be presenting at Life Science Innovation Northwest 2024 on April 18th! Her presentation will be part of the Central Nervous System and Autoimmune Diseases portion of the company presentations. Follow the link to see the full schedule.

#Innovation #AlzheimersDisease #Research #Seattle

ALTP

COM:ALTPEP

AltPep